Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Adcetris
ADCETRIS 50 mg powder for concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 13
HOS-126022 · Präparat HOS-096209
Cyclophosphamide, doxorubicin and prednisone (CHP)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cyclophosphamide (HOS-084539) doxorubicin (HOS-084538) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-20T10:51:00Z · SHA-256 a80608da289c54a95c6f3ae56a63c85084ccf90e8e43e395dd22479d252877cb · Passage afccb38fd3406ddca76df8f113e4fd52c986e6963194c817e9dbe64a125aa2cd · Zeichen 1461–1511 im Abschnitt
Wechselwirkungen · Docetaxel Accord
Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 11
HOS-126711 · Präparat HOS-096309
Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with metastatic
prostate cancer. Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4.
No statistically significant effect of prednisone on the pharmacokinetics of docetaxel was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-13T16:39:00Z · SHA-256 d97e7b4032943cf3884a7cbbb15dd1e84fa3ec25adf59d53d9e453c89968c5ae · Passage 7a86ffe04c9d854ec7ff58f6c6fb15794ace3c4d1a11379af6cf443cf6096284 · Zeichen 1271–1562 im Abschnitt
Gegenanzeigen · Xofigo
Xofigo 1100 kBq/mL solution for injection · Abschnitt 4.3 · PDF-Seite 4
HOS-128182 · Präparat HOS-096525
Xofigo is contraindicated in combination with abiraterone acetate and prednisone/prednisolone (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisolone (HOS-086337) abiraterone acetate (HOS-125271) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-30T14:59:00Z · SHA-256 2bc8e88ff62751c132e9d1a925ea99cae9b2a2bdea846ae42676e4b50d70bb74 · Passage 660242e7b0da4d6f66f62eb5f70b80c57269c1cd86b210d8733e9da3ceb79497 · Zeichen 0–112 im Abschnitt
Wechselwirkungen · Latuda
Latuda 18.5 mg film-coated tablets Latuda 37 mg film-coated tablets Latuda 74 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-128670 · Präparat HOS-096607
Coadministration of lurasidone with mild (e.g. armodafinil, amprenavir, aprepitant, prednisone,
rufinamide) or moderate (e.g. bosentan, efavirenz, etravirine, modafinil, nafcillin) inducers of
CYP3A4 would be expected to give a <2-fold reduction in lurasidone exposure during
co-administration and for up to 2 weeks after discontinuation of mild or moderate CYP3A4 inducers.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): armodafinil (HOS-128671) rufinamide (HOS-115232) modafinil (HOS-090546) aprepitant (HOS-112506) etravirine (HOS-088088) nafcillin (HOS-125452) amprenavir (HOS-086183) efavirenz (HOS-087947) bosentan (HOS-086291) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T16:17:00Z · SHA-256 1b4eb934eea6c777e082db5accb51f11c854318bf5d2d82b61249264a6b6a684 · Passage ba79ab260f6eb7e32fe670de16b33447a8f83d1a7ad03837bf3d6c29fa902f42 · Zeichen 3208–3582 im Abschnitt
Wechselwirkungen · Cresemba
CRESEMBA 200 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 6
HOS-128872 · Präparat HOS-096645
Co-administration with mild CYP3A4/5 inducers such as aprepitant, prednisone and pioglitazone, may
result in mild to moderate decreases of isavuconazole plasma levels; co-administration with mild
CYP3A4/5 inducers should be avoided unless the potential benefit is considered to outweigh the risk
(see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): aprepitant (HOS-112506) pioglitazone (HOS-089663) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage aeb053a95ea460d4b752b0235ada96817e514324020610e2d8ad85024bfb0c8d · Zeichen 1688–2002 im Abschnitt
Wechselwirkungen · Cresemba
CRESEMBA 200 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 8
HOS-128901 · Präparat HOS-096645
(UGT inhibition)
Prednisone Prednisolone (active metabolite): Co-administration should be
(CYP3A4 substrate) AUCinf: ↑ 8% avoided unless the potential
Cmax: ↓ 4% benefit is considered to outweigh
the risk.
(CYP3A4 inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisolone (HOS-086337) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage c9a7d3227a768ef7fbab5842a2e3c65ebb9a411c85fc1c9787559c9665392374 · Zeichen 8447–8882 im Abschnitt
Wechselwirkungen · Cresemba
CRESEMBA 40 mg hard capsules CRESEMBA 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 29
HOS-128960 · Präparat HOS-096645
Co-administration with mild CYP3A4/5 inducers such as aprepitant, prednisone and pioglitazone, may
result in mild to moderate decreases of isavuconazole plasma levels; co-administration with mild
CYP3A4/5 inducers should be avoided unless the potential benefit is considered to outweigh the risk
(see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): aprepitant (HOS-112506) pioglitazone (HOS-089663) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage aeb053a95ea460d4b752b0235ada96817e514324020610e2d8ad85024bfb0c8d · Zeichen 1746–2060 im Abschnitt
Wechselwirkungen · Cresemba
CRESEMBA 40 mg hard capsules CRESEMBA 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 31
HOS-128984 · Präparat HOS-096645
(UGT inhibition)
Prednisone Prednisolone (active metabolite): Co-administration should be
(CYP3A4 substrate) AUCinf: ↑ 8% avoided unless the potential
Cmax: ↓ 4% benefit is considered to outweigh
the risk.
(CYP3A4 inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisolone (HOS-086337) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage 1cf455188098efd3ec463b750ec12e18cfdb708d4bb1b4683a070a4e462fe557 · Zeichen 8605–9054 im Abschnitt
Wechselwirkungen · Tivicay
Tivicay 10 mg film-coated tablets Tivicay 25 mg film-coated tablets Tivicay 50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-129166 · Präparat HOS-096689
9
Magnesium/ Dolutegravir Magnesium/ aluminium-containing antacid should
aluminium-containing AUC 74% be taken well separated in time from the
antacid Cmax 72% administration of dolutegravir (minimum 2 hours
(Complex binding to after or 6 hours before).
polyvalent ions)
Calcium supplements Dolutegravir - When taken with food, Tivicay and supplements
(fasted intake) AUC 39% or multivitamins containing calcium, iron or
Cmax 37% magnesium can be taken at the same time.
C24 39% - If Tivicay is taken in a fasted state, such
(Complex binding to supplements should be taken a minimum 2 hours
polyvalent ions) after or 6 hours before the intake of Tivicay.
Iron supplements Dolutegravir
(fasted intake) AUC 54% The stated reductions in dolutegravir exposure
Cmax 57% were observed with the intake of dolutegravir and
C24 56% these supplements during fasted conditions. In fed
(Complex binding to state, the changes in exposure following intake
polyvalent ions) together with calcium or iron supplements were
Multivitamin Dolutegravir modified by the food effect, resulting in an
(containing calcium, AUC 33% exposure similar to that obtained with dolutegravir
iron and magnesium) Cmax 35% administered in the fasted state.
(fasted intake) C24 32%
(Complex binding to
polyvalent ions)
Corticosteroids
Prednisone Dolutegravir No dose adjustment is necessary.
AUC 11%
Cmax 6%
Cτ 17%
Antidiabetics
Metformin Metformin A dose adjustment of metformin should be
When co-administered with considered when starting and stopping
dolutegravir 50mg once coadministration of dolutegravir with metformin,
daily: to maintain glycaemic control. In patients with
Metformin moderate renal impairment a dose adjustment of
AUC 79% metformin should be considered when
Cmax 66% coadministered with dolutegravir, because of the
When co-administered with increased risk for lactic acidosis in patients with
dolutegravir 50mg twice moderate renal impairment due to increased
daily: metformin concentration (section 4.4).
Metformin
AUC 145 %
Cmax 111%
Antimycobacterials
Rifampicin Dolutegravir The recommended adult dose of dolutegravir is
AUC 54% 50 mg twice daily when co-administered with
Cmax 43% rifampicin in the absence of integrase class
Cτ 72% resistance. In paediatric patients the weight-based
(induction of UGT1A1 and once daily dose should be administered twice
CYP3A enzymes) daily.
In the presence of integrase class resistance this
combination should be avoided (see section 4.4).
Rifabutin Dolutegravir No dose adjustment is necessary.
AUC 5%
Cmax 16%
Cτ 30%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) calcium (HOS-085615) iron (HOS-085656) magnesium (HOS-085165) prednisone (HOS-084526) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:54:00Z · SHA-256 49ffb99144edc826feca26a0b941946b69a295b5c67e5f5fd79358277916c087 · Passage f7cdc948f0f37aad9317a603dc4efadabd031fe5fda7aad9c55b87b5ea9476f5 · Zeichen 13303–17453 im Abschnitt
Wechselwirkungen · Tivicay
Tivicay 5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 39–40
HOS-129201 · Präparat HOS-096689
39
Calcium supplements Dolutegravir - When taken with food, Tivicay and supplements
(fasted intake) AUC 39% or multivitamins containing calcium, iron or
Cmax 37% magnesium can be taken at the same time.
C24 39% - If Tivicay is taken in a fasted state, such
(Complex binding to supplements should be taken a minimum 2 hours
polyvalent ions) after or 6 hours before the intake of Tivicay.
Iron supplements Dolutegravir
(fasted intake) AUC 54% The stated reductions in dolutegravir exposure
Cmax 57% were observed with the intake of dolutegravir and
C24 56% these supplements during fasted conditions. In fed
(Complex binding to state, the changes in exposure following intake
polyvalent ions) together with calcium or iron supplements were
Multivitamin Dolutegravir modified by the food effect, resulting in an
(containing calcium, AUC 33% exposure similar to that obtained with dolutegravir
iron and magnesium) Cmax 35% administered in the fasted state.
(fasted intake) C24 32%
(Complex binding to
polyvalent ions)
Corticosteroids
Prednisone Dolutegravir No dose adjustment is necessary.
AUC 11%
Cmax 6%
Cτ 17%
Antidiabetics
Metformin Metformin A dose adjustment of metformin should be
When co-administered with considered when starting and stopping
dolutegravir 50mg film- coadministration of dolutegravir with metformin,
coated tablets once daily: to maintain glycaemic control. In patients with
Metformin moderate renal impairment a dose adjustment of
AUC 79% metformin should be considered when
Cmax 66% coadministered with dolutegravir, because of the
When co-administered with increased risk for lactic acidosis in patients with
dolutegravir 50mg film- moderate renal impairment due to increased
coated tablets twice daily: metformin concentration (section 4.4).
Metformin
AUC 145 %
Cmax 111%
Antimycobacterials
Rifampicin Dolutegravir The recommended adult dose of dolutegravir
AUC 54% should be given twice daily when co-administered
Cmax 43% with rifampicin in the absence of integrase class
Cτ 72% resistance. In paediatric patients the weight-based
(induction of UGT1A1 and once daily dose should be administered twice
CYP3A enzymes) daily.
In the presence of integrase class resistance this
combination should be avoided (see section 4.4).
Rifabutin Dolutegravir No dose adjustment is necessary.
AUC 5%
Cmax 16%
Cτ 30%
(induction of UGT1A1 and
CYP3A enzymes)
Oral contraceptives
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) calcium (HOS-085615) iron (HOS-085656) magnesium (HOS-085165) prednisone (HOS-084526) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:54:00Z · SHA-256 49ffb99144edc826feca26a0b941946b69a295b5c67e5f5fd79358277916c087 · Passage cf7ded37100a7c771efb0096a21a323a6de8cfc601cd1795a94f75791a79825c · Zeichen 13895–17824 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-129278 · Präparat HOS-096703
13
Magnesium/ Dolutegravir ↓ Magnesium/ aluminium-containing
aluminium-containing AUC ↓ 74% antacids should be taken well separated
antacids/Dolutegravir Cmax ↓ 72% in time from the administration of
Triumeq (minimum 2 hours after or 6
(Complex binding to hours before the intake of Triumeq).
polyvalent ions)
Calcium Dolutegravir ↓ - When taken with food, Triumeq and
supplements/Dolutegravir AUC ↓ 39% supplements or multivitamins containing
Cmax ↓ 37% calcium, iron or magnesium can be taken
C24 ↓ 39% at the same time.
(Complex binding to - If Triumeq is taken in a fasted state,
polyvalent ions) such supplements should be taken a
Iron supplements/Dolutegravir Dolutegravir ↓ minimum 2 hours after or 6 hours before
AUC ↓ 54% the intake of Triumeq.
Cmax ↓ 57%
C24 ↓ 56% The stated reductions in dolutegravir
(Complex binding to exposure were observed with the intake
polyvalent ions) of dolutegravir and these supplements
Multivitamins (containing Dolutegravir ↓ during fasted conditions. In fed state, the
calcium, iron and magnesium) AUC ↓ 33% changes in exposure following intake
/Dolutegravir Cmax ↓ 35% together with calcium or iron
C24 ↓ 32% supplements were modified by the food
effect, resulting in an exposure similar to
that obtained with dolutegravir
administered in the fasted state.
Corticosteroids
Prednisone Dolutegravir ↔ No dose adjustment is necessary.
AUC ↑ 11%
Cmax ↑ 6%
Cτ ↑ 17%
Antidiabetics
Metformin/Dolutegravir Metformin ↑ A dose adjustment of metformin should
Dolutegravir ↔ be considered when starting and
When co-administered stopping coadministration of
with dolutegravir 50mg dolutegravir with metformin, to maintain
QD: glycaemic control. In patients with
Metformin moderate renal impairment a dose
AUC ↑ 79% adjustment of metformin should be
Cmax ↑ 66% considered when coadministered with
When co-administered dolutegravir, because of the increased
with dolutegravir 50mg risk for lactic acidosis in patients with
BID: moderate renal impairment due to
Metformin increased metformin concentration
AUC ↑ 145 % (section 4.4).
Cmax ↑ 111%
Herbal products
St. John’s wort/Dolutegravir Dolutegravir↓ The recommended dose of dolutegravir
(Not studied, decrease is 50 mg twice daily when co-
expected due to induction administered with St. John’s wort. As
of UGT1A1 and CYP3A Triumeq is a fixed dose tablet, an
enzymes, a similar additional 50 mg tablet of dolutegravir
reduction in exposure as should be administered, approximately
observed with 12 hours after Triumeq for the duration
carbamazepine is of the St John’s wort co-administration
expected) (a separate preparation of dolutegravir is
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) calcium (HOS-085615) iron (HOS-085656) magnesium (HOS-085165) prednisone (HOS-084526) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage c8fee2375199538a75c25c7b72890728decb53cdd903d7de9ec1464e917c5665 · Zeichen 24627–29346 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 5 mg/60 mg/30 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 50–52
HOS-129364 · Präparat HOS-096703
50
(Complex binding to The stated reductions in dolutegravir
polyvalent ions) exposure were observed with the intake
Multivitamins (containing Dolutegravir ↓ of dolutegravir and these supplements
calcium, iron and magnesium) AUC ↓ 33% during fasted conditions. In fed state, the
/Dolutegravir Cmax ↓ 35% changes in exposure following intake
C24 ↓ 32% together with calcium or iron
supplements were modified by the food
effect, resulting in an exposure similar to
that obtained with dolutegravir
administered in the fasted state.
Corticosteroids
Prednisone Dolutegravir ↔ No dose adjustment is necessary.
AUC ↑ 11%
Cmax ↑ 6%
Cτ ↑ 17%
Antidiabetics
Metformin/Dolutegravir Metformin ↑ A dose adjustment of metformin should
Dolutegravir ↔ be considered when starting and
When co-administered stopping coadministration of
with dolutegravir 50mg dolutegravir with metformin, to maintain
QD: glycaemic control. In patients with
Metformin moderate renal impairment a dose
AUC ↑ 79% adjustment of metformin should be
Cmax ↑ 66% considered when coadministered with
When co-administered dolutegravir, because of the increased
with dolutegravir 50mg risk for lactic acidosis in patients with
BID: moderate renal impairment due to
Metformin increased metformin concentration
AUC ↑ 145 % (section 4.4).
Cmax ↑ 111%
Herbal products
St. John’s wort/Dolutegravir Dolutegravir↓ The recommended dose of dolutegravir
(Not studied, decrease should be adjusted when co-
expected due to induction administered with St. John’s wort.
of UGT1A1 and CYP3A
enzymes, a similar Dosing recommendations are provided
reduction in exposure as in Table 2 (see section 4.2)
observed with
carbamazepine is
expected)
Oral contraceptives
Ethinyl estradiol (EE) and Effect of dolutegravir: Dolutegravir had no Pharmacodynamic
Norgestromin EE ↔ effect on Luteinizing Hormone (LH),
(NGMN)/Dolutegravir AUC ↑ 3% Follicle Stimulating Hormone (FSH) and
Cmax ↓ 1% progesterone. No dose adjustment of
oral contraceptives is necessary when
Effect of dolutegravir: co-administered with Triumeq.
NGMN ↔
AUC ↓ 2%
Cmax ↓ 11%
Antihypertensive
Riociguat/Abacavir Riociguat ↑ Riociguat dose may need to be reduced,
consult the riociguat prescribing
In vitro, abacavir inhibits
information for dosing
CYP1A1. Concomitant
recommendations.
administration of a single
51
dose of riociguat (0.5 mg)
to HIV patients receiving
Triumeq led to an
approximately three-fold
higher riociguat AUC(0-∞)
when compared to
historical riociguat
AUC(0-∞) reported in
healthy subjects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) follicle stimulating hormone (HOS-123034) riociguat (HOS-086293) carbamazepine (HOS-085618) ethinyl estradiol (HOS-088135) calcium (HOS-085615) iron (HOS-085656) luteinizing hormone (HOS-090752) magnesium (HOS-085165) prednisone (HOS-084526) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 4f0d85e516680fd44841c8a2084bad237df81c83647e075fbfa5f388b51c50c4 · Zeichen 22392–27416 im Abschnitt
Wechselwirkungen · Oncaspar
Oncaspar 750 U/ml powder for solution for injection/infusion. · Abschnitt 4.5 · PDF-Seite 6
HOS-131517 · Präparat HOS-097087
When glucocorticoids (e.g., prednisone) and pegaspargase are given at the same time, alterations in
coagulation parameters (e.g., fall in fibrinogen and antithrombin III deficiency, ATIII) can be more
pronounced.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fibrinogen (HOS-131518) prednisone (HOS-084526) antithrombin III (HOS-131519)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T15:25:00Z · SHA-256 76dc9eed7dc8fae840aac8646ddfd5b804f415269fe1e076c1b8ee3a8fd6ae06 · Passage 6f7fe4731dcaae891be3f12d514ea2322eacad5772496e677b4e35a5110c25af · Zeichen 1274–1486 im Abschnitt
Wechselwirkungen · Bortezomib Accord
Bortezomib Accord 2.5 mg/mL solution for injection · Abschnitt 4.5 · PDF-Seite 13
HOS-133275 · Präparat HOS-097412
A drug-drug interaction study assessing the effect of melphalan-prednisone on the pharmacokinetics of
bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 17% based on data
from 21 patients. This is not considered clinically relevant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-25T15:00:00Z · SHA-256 95954b33292c291c1f0b9499f65ea0d9efd1266892e12a142f48541fdf5605bb · Passage 9e907f51e48442d1b2e301d7690958ff791903a16ae93aa6d76a2b4cca6ab4bd · Zeichen 1746–2005 im Abschnitt
Wechselwirkungen · Bortezomib Accord
Bortezomib Accord 1 mg powder for solution for injection Bortezomib Accord 3.5 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 46
HOS-133312 · Präparat HOS-097412
A drug-drug interaction study assessing the effect of melphalan-prednisone on the pharmacokinetics of
bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 17% based on data
from 21 patients. This is not considered clinically relevant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-25T15:00:00Z · SHA-256 95954b33292c291c1f0b9499f65ea0d9efd1266892e12a142f48541fdf5605bb · Passage 9e907f51e48442d1b2e301d7690958ff791903a16ae93aa6d76a2b4cca6ab4bd · Zeichen 1746–2005 im Abschnitt
Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-133968 · Präparat HOS-097520
13
Medicinal product by Effects on medicinal product Recommendation concerning
therapeutic areas levels. co-administration with Genvoya
Mean percent change in AUC,
Cmax, Cmin1
GLUCOCORTICOIDS
Corticosteroids
Corticosteroids primarily Interaction not studied with any of Concomitant use of Genvoya and
metabolised by CYP3A (including the components of Genvoya. corticosteroids that are metabolised
betamethasone, budesonide, by CYP3A (e.g. fluticasone
fluticasone, mometasone, Plasma concentrations of these propionate or other inhaled or nasal
prednisone, triamcinolone). medicinal products may be corticosteroids) may increase the
increased when co-administered risk of development of systemic
with Genvoya, resulting in reduced corticosteroid effects, including
serum cortisol concentrations. Cushing’s syndrome and adrenal
suppression.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triamcinolone (HOS-086333) fluticasone (HOS-108914) betamethasone (HOS-090066) budesonide (HOS-086332) mometasone (HOS-114048) propionate (HOS-108915) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 4acfffdad184917b98d978a921f68a1280a07b1ef57cf90080b742c333a4288d · Zeichen 20863–22145 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 17–18
HOS-134507 · Präparat HOS-097580
17
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
Perphenazine Not studied. Darunavir is expected to A dose decrease may be needed for
Risperidone increase these antipsychotic plasma these drugs when co-administered
Thioridazine concentrations. with darunavir co-administered with
(CYP3A, CYP2D6 and/or P-gp low dose ritonavir.
inhibition)
Lurasidone Pimozide Concomitant administration of
Sertindole darunavir with low dose ritonavir
and lurasidone, pimozide or
sertindole is contraindicated (see
section 4.3).
β-BLOCKERS
Carvedilol Not studied. Darunavir is expected to Clinical monitoring is
Metoprolol increase these β-blocker plasma recommended when co-
Timolol concentrations. administering darunavir with β-
(CYP2D6 inhibition) blockers. A lower dose of the β-
blocker should be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Darunavir co-administered Clinical monitoring of therapeutic
Diltiazem with low dose ritonavir can be and adverse effects is recommended
Felodipine expected to increase the plasma when these medicines are
Nicardipine concentrations of calcium channel concomitantly administered with
Nifedipine blockers. darunavir with low dose ritonavir.
Verapamil (CYP3A and/or CYP2D6 inhibition)
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of darunavir with
metabolised by CYP3A ritonavir 100 mg capsules twice daily low dose ritonavir and
(including betamethasone, were co-administered with 50 μg corticosteroids (all routes of
budesonide, fluticasone, intranasal fluticasone propionate (4 administration) that are metabolised
mometasone, prednisone, times daily) for 7 days in healthy by CYP3A may increase the risk of
triamcinolone) subjects, fluticasone propionate plasma development of systemic
concentrations increased significantly, corticosteroid effects, including
whereas the intrinsic cortisol levels Cushing’s syndrome and adrenal
decreased by approximately 86% (90% suppression.
CI 82-89%). Greater effects may be
expected when fluticasone is inhaled. Co-administration with CYP3A-
Systemic corticosteroid effects metabolised corticosteroids is not
including Cushing’s syndrome and recommended unless the potential
adrenal suppression have been reported benefit to the patient outweighs the
in patients receiving ritonavir and risk, in which case patients should
inhaled or intranasally administered be monitored for systemic
fluticasone. The effects of high corticosteroid effects.
fluticasone systemic exposure on
ritonavir plasma levels are unknown. Alternative corticosteroids which
are less dependent on CYP3A
Other corticosteroids: interaction not metabolism e.g. beclomethasone
studied. Plasma concentrations of these should be considered, particularly
medicinal products may be increased for long term use.
when co-administered with darunavir
with low dose ritonavir, resulting in
reduced serum cortisol concentrations.
Dexamethasone (systemic) Not studied. Dexamethasone may Systemic dexamethasone should be
decrease plasma concentrations of used with caution when combined
darunavir. (CYP3A induction) with darunavir co-administered with
low dose ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 4d699252eaa8e454816efcf834725c875d4dc8037df504e7418d309238a96785 · Zeichen 43154–48076 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59–60
HOS-134627 · Präparat HOS-097580
59
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
Perphenazine Not studied. Boosted darunavir is A dose decrease may be needed for
Risperidone expected to increase these these drugs when co-administered
Thioridazine antipsychotic plasma with boosted darunavir.
concentrations. (CYP3A, CYP2D6
and/or P-gp inhibition)
Lurasidone Concomitant administration of
Pimozide boosted darunavir and lurasidone,
Sertindole pimozide or sertindole is
contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted darunavir is Clinical monitoring is recommended
Metoprolol expected to increase these β-blocker when co-administering boosted
Timolol plasma concentrations. darunavir with β-blockers. A lower
(CYP2D6 inhibition) dose of the β-blocker should be
considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted darunavir can Clinical monitoring of therapeutic
Diltiazem be expected to increase the plasma and adverse effects is recommended
Felodipine concentrations of calcium channel when these medicines are
Nicardipine blockers. concomitantly administered with
Nifedipine (CYP3A and/or CYP2D6 boosted darunavir.
Verapamil inhibition)
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study Concomitant use of boosted
metabolised by CYP3A where ritonavir 100 mg capsules darunavir and corticosteroids (all
(including betamethasone, twice daily were co-administered routes of administration) that are
budesonide, fluticasone, with 50 μg intranasal fluticasone metabolised by CYP3A may increase
mometasone, prednisone, propionate (4 times daily) for 7 the risk of development of systemic
triamcinolone) days in healthy subjects, fluticasone corticosteroid effects, including
propionate plasma concentrations Cushing’s syndrome and adrenal
increased significantly, whereas the suppression.
intrinsic cortisol levels decreased
by approximately 86% (90% CI 82- Co-administration with CYP3A-
89%). Greater effects may be metabolised corticosteroids is not
expected when fluticasone is recommended unless the potential
inhaled. Systemic corticosteroid benefit to the patient outweighs the
effects including Cushing's risk, in which case patients should be
syndrome and adrenal suppression monitored for systemic corticosteroid
have been reported in patients effects.
receiving ritonavir and inhaled or
intranasally administered Alternative corticosteroids which are
fluticasone. The effects of high less dependent on CYP3A
fluticasone systemic exposure on metabolism
ritonavir plasma levels are e.g. beclomethasone should be
unknown. considered, particularly for long term
use.
Other corticosteroids: interaction
not studied. Plasma concentrations
of these medicinal products may be
increased when co-administered
with boosted darunavir, resulting in
reduced serum cortisol
concentrations.
Dexamethasone (systemic) Not studied. Dexamethasone may Systemic dexamethasone should be
decrease plasma concentrations of used with caution when combined
darunavir. with boosted darunavir.
(CYP3A induction)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) propionate (HOS-108915) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 5be93392fc9daddc5a4bddcaf5177effda2055057fdf350b6c14c2d3c31e17fc · Zeichen 49576–54404 im Abschnitt
Wechselwirkungen · Darzalex
DARZALEX 1800 mg solution for injection · Abschnitt 4.5 · PDF-Seite 42
HOS-134746 · Präparat HOS-097602
Clinical pharmacokinetic assessments with daratumumab intravenous or subcutaneous formulations
and lenalidomide, pomalidomide, thalidomide, bortezomib, melphalan, prednisone, carfilzomib,
cyclophosphamide and dexamethasone indicated no clinically-relevant drug-drug interaction between
daratumumab and these small molecule medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): melphalan (HOS-088956) carfilzomib (HOS-131552) pomalidomide (HOS-134715) lenalidomide (HOS-117069) dexamethasone (HOS-084535) bortezomib (HOS-110227) cyclophosphamide (HOS-084539) thalidomide (HOS-108445) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T17:24:00Z · SHA-256 c12cd50042ee3c8bfacfaf0749a9130a914836799423843163f544e5fb95aff4 · Passage c28cf90d19154876d922c603641afde706f0dadbce71deac5e75ee0b655c4a64 · Zeichen 492–834 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-138490 · Präparat HOS-098200
Lurasidone The combination of lurasidone,
Pimozide pimozide, quetiapine or sertindole
Quetiapine and Symtuza is contraindicated
Sertindole (see section 4.3).
β-BLOCKERS
Carvedilol Based on theoretical considerations Clinical monitoring is
Metoprolol DRV/COBI is expected to increase recommended when
Timolol these beta-blocker plasma co-administering Symtuza with
concentrations. beta-blockers and a lower dose of
(CYP2D6 inhibition) the beta-blocker should be
considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Based on theoretical considerations Clinical monitoring is
Diltiazem DRV/COBI is expected to increase recommended when these
Felodipine these calcium channel blocker medicinal products are
Nicardipine plasma concentrations. co-administered with Symtuza.
Nifedipine (CYP3A inhibition)
Verapamil
CORTICOSTEROIDS
Corticosteroids primarily Based on theoretical considerations Concomitant use of Symtuza and
metabolised by CYP3A DRV/COBI is expected to increase corticosteroids (all routes of
(including betamethasone, these corticosteroid plasma administration) that are
budesonide, fluticasone, concentrations. metabolised by CYP3A may
mometasone, prednisone, (CYP3A inhibition) increase the risk for development
triamcinolone) of systemic corticosteroid effects,
including Cushing’s syndrome
and adrenal suppression.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) carvedilol (HOS-115322) amlodipine (HOS-086287) calcium (HOS-085615) betamethasone (HOS-090066) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 93d51832ca83543fafde6c13b4aad3650a78fd53d8dfafa10a844085355fa52e · Zeichen 24581–26821 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.